Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial

Area of Science:

• Rheumatology
• Immunology
• Internal Medicine

Background:

• ANCA-associated vasculitis (AAV) survival has improved, yet mortality remains elevated.
• Glucocorticoids are associated with significant morbidity and mortality in AAV patients.
• Novel therapeutic strategies are needed to improve outcomes and reduce treatment burden.

Purpose of the Study:

• To evaluate the efficacy of an 8-week glucocorticoid (prednisone) course combined with rituximab (RTX) for inducing disease remission in AAV.
• To assess the safety and relapse rates associated with this abbreviated glucocorticoid regimen.

Main Methods:

• A prospective study involving 20 active AAV patients receiving an 8-week prednisone taper and RTX.
• Exclusion criteria included severe glomerulonephritis or diffuse alveolar hemorrhage requiring mechanical ventilation.
• Primary endpoint: complete remission at 24 weeks, defined as no disease activity off prednisone without relapse.

Main Results:

• 70% of patients achieved complete remission at 24 weeks.
• The remission rate was comparable to historical controls from the RAVE trial (adjusted OR 1.31).
• Fewer adverse events (median 2 vs. 8) were observed, but relapse rates were higher (30% vs. 7%).

Conclusions:

• An 8-week prednisone and RTX regimen can induce remission in AAV patients with fewer adverse events.
• This approach, however, is associated with an increased risk of relapse, particularly in patients with severe initial manifestations.
• Further investigation in selected patient populations is warranted to optimize this treatment protocol.